S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.47 (-0.27%)
AAPL   149.11 (+0.24%)
MSFT   307.19 (-0.34%)
FB   340.60 (+0.18%)
GOOGL   2,831.55 (-1.16%)
TSLA   862.94 (-0.15%)
AMZN   3,411.10 (-0.96%)
NVDA   221.03 (-0.84%)
BABA   177.15 (+0.08%)
NIO   39.56 (-1.17%)
CGC   14.25 (-0.63%)
GE   105.95 (+1.16%)
AMD   116.28 (-0.04%)
MU   68.06 (+0.73%)
T   25.90 (+1.21%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.16 (-0.60%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.77 (-0.07%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.47 (-0.27%)
AAPL   149.11 (+0.24%)
MSFT   307.19 (-0.34%)
FB   340.60 (+0.18%)
GOOGL   2,831.55 (-1.16%)
TSLA   862.94 (-0.15%)
AMZN   3,411.10 (-0.96%)
NVDA   221.03 (-0.84%)
BABA   177.15 (+0.08%)
NIO   39.56 (-1.17%)
CGC   14.25 (-0.63%)
GE   105.95 (+1.16%)
AMD   116.28 (-0.04%)
MU   68.06 (+0.73%)
T   25.90 (+1.21%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.16 (-0.60%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.77 (-0.07%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.47 (-0.27%)
AAPL   149.11 (+0.24%)
MSFT   307.19 (-0.34%)
FB   340.60 (+0.18%)
GOOGL   2,831.55 (-1.16%)
TSLA   862.94 (-0.15%)
AMZN   3,411.10 (-0.96%)
NVDA   221.03 (-0.84%)
BABA   177.15 (+0.08%)
NIO   39.56 (-1.17%)
CGC   14.25 (-0.63%)
GE   105.95 (+1.16%)
AMD   116.28 (-0.04%)
MU   68.06 (+0.73%)
T   25.90 (+1.21%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.16 (-0.60%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.77 (-0.07%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.47 (-0.27%)
AAPL   149.11 (+0.24%)
MSFT   307.19 (-0.34%)
FB   340.60 (+0.18%)
GOOGL   2,831.55 (-1.16%)
TSLA   862.94 (-0.15%)
AMZN   3,411.10 (-0.96%)
NVDA   221.03 (-0.84%)
BABA   177.15 (+0.08%)
NIO   39.56 (-1.17%)
CGC   14.25 (-0.63%)
GE   105.95 (+1.16%)
AMD   116.28 (-0.04%)
MU   68.06 (+0.73%)
T   25.90 (+1.21%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.16 (-0.60%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.77 (-0.07%)

Outlook Therapeutics Stock Forecast, Price & News

$2.13
+0.02 (+0.95 %)
(As of 10/20/2021 03:59 PM ET)
Add
Compare
Today's Range
$2.11
$2.16
50-Day Range
$2.09
$2.76
52-Week Range
$0.69
$4.26
Volume11,152 shs
Average Volume2.81 million shs
Market Capitalization$373.48 million
P/E RatioN/A
Dividend YieldN/A
Beta0.77
30 days | 90 days | 365 days | Advanced Chart
Receive OTLK News and Ratings via Email

Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Outlook Therapeutics logo

About Outlook Therapeutics

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OTLK
Employees
8
Year Founded
N/A

Sales & Book Value

Annual Sales
$8.15 million
Book Value
$0.02 per share

Profitability

Net Income
$-35.24 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$373.48 million
Next Earnings Date
12/22/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

844th out of 1,360 stocks

Biological Products, Except Diagnostic Industry

126th out of 196 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Outlook Therapeutics (NASDAQ:OTLK) Frequently Asked Questions

Is Outlook Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Outlook Therapeutics stock.
View analyst ratings for Outlook Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Outlook Therapeutics?

Wall Street analysts have given Outlook Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Outlook Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Outlook Therapeutics' next earnings date?

Outlook Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, December 22nd 2021.
View our earnings forecast for Outlook Therapeutics
.

How were Outlook Therapeutics' earnings last quarter?

Outlook Therapeutics, Inc. (NASDAQ:OTLK) issued its quarterly earnings data on Thursday, August, 12th. The company reported ($0.07) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.07).
View Outlook Therapeutics' earnings history
.

How has Outlook Therapeutics' stock been impacted by Coronavirus?

Outlook Therapeutics' stock was trading at $0.6601 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OTLK stock has increased by 224.2% and is now trading at $2.14.
View which stocks have been most impacted by COVID-19
.

When did Outlook Therapeutics' stock split? How did Outlook Therapeutics' stock split work?

Outlook Therapeutics's stock reverse split before market open on Monday, March 18th 2019. The 1-8 reverse split was announced on Friday, March 15th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 15th 2019. An investor that had 100 shares of Outlook Therapeutics stock prior to the reverse split would have 13 shares after the split.

What price target have analysts set for OTLK?

2 Wall Street analysts have issued 12-month price objectives for Outlook Therapeutics' shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate Outlook Therapeutics' share price to reach $6.00 in the next year. This suggests a possible upside of 180.4% from the stock's current price.
View analysts' price targets for Outlook Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Outlook Therapeutics' key executives?

Outlook Therapeutics' management team includes the following people:
  • C. Russell Trenary, President, Chief Executive Officer & Director
  • Terry Dagnon, Chief Operating Officer
  • Lawrence A. Kenyon, CFO, Secretary, Treasurer & Director
  • Jennifer M. Kissner, Senior Vice President-Clinical Development
  • Jeff Evanson, Chief Commercial Officer

What other stocks do shareholders of Outlook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), KushCo (KSHB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Novan (NOVN), OrganiGram (OGI) and Cannabics Pharmaceuticals (CNBX).

What is Outlook Therapeutics' stock symbol?

Outlook Therapeutics trades on the NASDAQ under the ticker symbol "OTLK."

Who are Outlook Therapeutics' major shareholders?

Outlook Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Coastal Investment Advisors Inc. (0.01%). Company insiders that own Outlook Therapeutics stock include Faisal Ghiath Sukhtian, Ghiath M Sukhtian, Jeff Evanson, Randy H Thurman, Syntone Ventures Llc, Terry Dagnon and Yezan Munther Haddadin.
View institutional ownership trends for Outlook Therapeutics
.

Which major investors are buying Outlook Therapeutics stock?

OTLK stock was purchased by a variety of institutional investors in the last quarter, including Coastal Investment Advisors Inc.. Company insiders that have bought Outlook Therapeutics stock in the last two years include Faisal Ghiath Sukhtian, Ghiath M Sukhtian, Randy H Thurman, Syntone Ventures Llc, and Yezan Munther Haddadin.
View insider buying and selling activity for Outlook Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Outlook Therapeutics?

Shares of OTLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Outlook Therapeutics' stock price today?

One share of OTLK stock can currently be purchased for approximately $2.14.

How much money does Outlook Therapeutics make?

Outlook Therapeutics has a market capitalization of $375.23 million and generates $8.15 million in revenue each year. The company earns $-35.24 million in net income (profit) each year or ($0.67) on an earnings per share basis.

How many employees does Outlook Therapeutics have?

Outlook Therapeutics employs 8 workers across the globe.

What is Outlook Therapeutics' official website?

The official website for Outlook Therapeutics is www.outlooktherapeutics.com.

Where are Outlook Therapeutics' headquarters?

Outlook Therapeutics is headquartered at 4260 U.S. ROUTE 1, MONMOUTH JUNCTION NJ, 08852.

How can I contact Outlook Therapeutics?

Outlook Therapeutics' mailing address is 4260 U.S. ROUTE 1, MONMOUTH JUNCTION NJ, 08852. The company can be reached via phone at (609) 619-3990 or via email at [email protected].


This page was last updated on 10/20/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.